Not Yet RecruitingNot Applicable

Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

200 participantsStarted 2026-04-01

Plain-language summary

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Type 2 diabetic patients Exclusion Criteria: * Non-diabetic kidney diseases. * Acute illness, infection, obesity, hypertension, type 1 DM. * Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.

What they're measuring

Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Timeframe: Two years

Trial details

NCT IDNCT07435480

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-03-01

Contact for this trial

Gehad Ha Abdelmegid, MD

00201125745717 gege1_8_1992@yahoo.com

View on ClinicalTrials.gov More Diabetic Nephropathies trials